1.89
0.53%
-0.01
After Hours:
1.89
Palatin Technologies Inc. stock is currently priced at $1.89, with a 24-hour trading volume of 180.63K.
It has seen a -0.53% decreased in the last 24 hours and a +18.12% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $1.89 pivot point. If it approaches the $1.96 resistance level, significant changes may occur.
Palatin Technologies Inc. Stock (PTN) Financials Data
Palatin Technologies Inc. (PTN) Revenue 2024
PTN reported a revenue (TTM) of $7.10 million for the quarter ending December 31, 2023, a +146.20% rise year-over-year.
Palatin Technologies Inc. (PTN) Net Income 2024
PTN net income (TTM) was -$31.59 million for the quarter ending December 31, 2023, a -21.77% decrease year-over-year.
Palatin Technologies Inc. (PTN) Cash Flow 2024
PTN recorded a free cash flow (TTM) of -$26.75 million for the quarter ending December 31, 2023, a +25.37% increase year-over-year.
Palatin Technologies Inc. (PTN) Earnings per Share 2024
PTN earnings per share (TTM) was -$2.61 for the quarter ending December 31, 2023, a +5.09% growth year-over-year.
Palatin Technologies Inc. Stock (PTN) Latest News
Palatin Technologies And 2 Other Stocks Under $3 Insiders Are Buying
Benzinga
Palatin (PTN) Up 15% on Results From Dry Eye Disease Study
Zacks Investment Research
Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
Dow Dips 200 Points; TJX Posts Upbeat Sales
Benzinga
Strength Seen in Repligen (RGEN): Can Its 4.3% Jump Turn into More Strength?
Zacks Investment Research
Why Getaround Shares Are Trading Higher By Around 86%; Here Are 20 Stocks Moving Premarket
Benzinga
About Palatin Technologies Inc.
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific therapeutics for the treatment of various diseases in the United States. The company's principal product is Vyleesi, an on demand subcutaneous injectable product that has completed Phase III clinical studies for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. Its drug development programs also include melanocortin receptor system program, such as PL-8177, a selective melanocortin receptor 1 agonist peptide for inflammatory bowel diseases; and PL-8331, a preclinical development candidate for treating ocular inflammation, as well as melanocortin receptor 4 peptides and orally-active small molecules to treat genetic metabolic and obesity disorders. In addition, the company develops natriuretic peptide receptor systems comprising PL3994, a natriuretic peptide receptor-A agonist, which has completed Phase I clinical study for the treatment of cardiovascular indications; and PL-5028, a dual natriuretic peptide receptor A and C agonist that is in preclinical development for cardiovascular diseases, such as reducing cardiac hypertrophy and fibrosis. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.
Cap:
|
Volume (24h):